United Therapeutics (NASDAQ:UTHR) COO Sells $10,617,975.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $471.91, for a total value of $10,617,975.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Tuesday, January 20th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The stock was sold at an average price of $464.66, for a total value of $6,795,652.50.
• On Tuesday, January 20th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The stock was sold at an average price of $464.66, for a total value of $3,659,197.50.
• On Monday, January 12th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.51, for a total value of $10,788,975.00.
• On Monday, January 5th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total value of $3,838,117.50.
• On Monday, January 5th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total transaction of $7,127,932.50.
• On Monday, December 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $502.79, for a total transaction of $11,312,775.00.
• On Monday, December 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $514.35, for a total transaction of $11,572,875.00.
• On Monday, December 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $496.30, for a total transaction of $11,166,750.00.
• On Monday, December 8th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $478.58, for a total transaction of $10,768,050.00.
• On Monday, December 1st, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $479.91, for a total value of $10,797,975.00.

United Therapeutics Trading Up 0.4%

Shares of NASDAQ UTHR opened at $469.49 on Friday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $519.99. The company has a market cap of $20.22 billion, a PE ratio of 17.79, a P/E/G ratio of 2.49 and a beta of 0.84. The stock has a 50 day simple moving average of $487.26 and a 200-day simple moving average of $420.14.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. During the same period last year, the firm earned $6.39 EPS. The firm’s revenue was up 6.8% compared to the same quarter last year. Sell-side analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Darwin Global Management Ltd. acquired a new position in shares of United Therapeutics in the 3rd quarter worth $317,617,000. Norges Bank acquired a new position in shares of United Therapeutics in the 2nd quarter valued at $136,453,000. Invesco Ltd. boosted its position in shares of United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after purchasing an additional 419,588 shares during the period. AQR Capital Management LLC increased its stake in United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after purchasing an additional 364,713 shares in the last quarter. Finally, Baillie Gifford & Co. acquired a new stake in United Therapeutics during the 4th quarter worth about $157,390,000. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the subject of several research analyst reports. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research note on Wednesday, October 29th. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. HC Wainwright boosted their target price on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Finally, UBS Group increased their price target on United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.